Real-World Evidence on Adjuvant Chemotherapy After Resection of Left-Sided Obstructive Colon Cancer
A bridge-to-surgery strategy did not influence adjuvant chemotherapy receipt in patients with LSOCC. Obstruction is considered a risk factor in stage II, but no survival benefit of adjuvant chemotherapy is seen for the pT3N0 subgroup.
Authors
- Henderik L. van Westreenen (ORCID: https://orcid.org/0000-0002-1910-2723)
- Esther C. J. Consten (ORCID: https://orcid.org/0000-0002-9447-8181)
- Bobby Zamaray (ORCID: https://orcid.org/0000-0002-2361-7578)
- Peter D. Siersema (ORCID: https://orcid.org/0000-0002-6940-8499)
- Jeanin E. van Hooft (ORCID: https://orcid.org/0000-0002-4424-0079)
- Pieter J. Tanis (ORCID: https://orcid.org/0000-0002-3146-3310)
- Jan Willem B. de Groot (ORCID: https://orcid.org/0000-0002-1043-5011)
- Niels F. M. Kok (ORCID: https://orcid.org/0000-0003-1193-0214)
Institutions
- University Medical Center Groningen (NL)
- Leiden University Medical Center (NL)
- Erasmus MC (NL)
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
- Isala (NL)
- Meander Medisch Centrum (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- Clinical Colorectal Cancer
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1016/j.clcc.2025.09.002
- Citations
- 1
- Primary Topic
- Colorectal Cancer Surgical Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Sanofi
- Boston Scientific Corporation
- Cook Medical
- Norgine